3 Pharmaceutical Stocks to Watch: Will They Get Healthy Today?

Alembic Pharmaceuticals Ltd has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa, Levodopa and Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg and 50 mg/200 mg/200 mg. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson’s disease.

IPCA Laboratories informed the exchanges that the manufacturing facility in Tarapur (Maharashtra) has now received a site inspection report classifying the manufacturing facility as “Voluntary Action Indicated (VAI)” and that this facility is considered to be in a minimum acceptable state of compliance with the US FDA’s Current Good Manufacturing Practices (CGMP).

Zydus Lifescience, a leading discovery-based global pharmaceutical company, announced that the USFDA has granted Orphan Drug Designation (ODD) to Desidustat, a novel oral HIF-PHI, for the treatment of sickle cell disease (SCD). The USFDA’s Office of Orphan Drug Products grants orphan drug designation to support the development of drugs to treat rare diseases that affect fewer than 200,000 people in the United States.

Published on February 9, 2026